Clinical Trials Logo

Clinical Trial Summary

Astragalus membranaceus (AM) is used to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. PG2, a sterile powder of polysaccharides isolated from the root of astragulus (Huang-Chi) for intravenous injection, has been approved as a botanical drug by TFDA. Hemorrhagic stroke will induce secondary peri-blood clot edema and that may increase intracranial pressure to exacerbate clinical symptom. Therefore, the purpose of the present study was to investigate the efficacy of PG2 on hemorrhagic stroke.


Clinical Trial Description

This will be a double-blind, randomized, placebo-controlled study. An estimated 60 (at least 48 evaluable) first hemorrhagic stroke patients will be randomly divided into the control and treatment groups. Each group will be treated as follows: 1) control group will accept placebo t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.; 2) treatment group will accept PG2 t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment. Inflammatory index including the levels of C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), S-100 protein, IL-1, IL-6, and TNF-beta levels will be measured and clinical symptoms including Glasgow outcome scale (GOS), modified rankin scale (MRS), Functional Independence Measure (FIM) and Barthel Index (BI) will be evaluated during this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01325233
Study type Interventional
Source PhytoHealth Corporation
Contact
Status Completed
Phase Early Phase 1
Start date March 2011
Completion date September 2013

See also
  Status Clinical Trial Phase
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Completed NCT01573117 - A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1) Phase 2
Completed NCT03292211 - The Effect of Early Mobilization in Mild to Moderate Hemorrhagic Stroke N/A
Not yet recruiting NCT06069973 - Using Machine Learning and Biomarkers for Early Detection of Delayed Cerebral Ischemia
Not yet recruiting NCT05816213 - Point-of-care Low-field MRI in Acute Stroke
Not yet recruiting NCT05502874 - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting NCT04534556 - Wireless Nerve Stimulation Device To Enhance Recovery After Stroke N/A
Recruiting NCT04200781 - Clinical Evaluation of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke Phase 4
Recruiting NCT05440682 - Connectivity in Cranioplasty N/A
Completed NCT05121415 - Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy
Terminated NCT02626377 - Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté N/A
Completed NCT01942031 - Improved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke) N/A
Completed NCT01845350 - Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients Phase 1
Recruiting NCT05865795 - Mapping the Natural History of Parenychymal and Cerebral Perfusion Changes in Acute Ischemic and Hemorrhagic Strokes
Completed NCT04612218 - Biomarkers for Initiating Onsite and Faster Ambulance Stroke Therapies
Recruiting NCT06134921 - Effects of Transcranial Electrical Stimulation in Stroke Individuals N/A
Recruiting NCT06190314 - SERUM VITAMIN B12 LEVELS IN PATIENTS WITH HEMORRHAGIC VS ISCHEMIC CEREBROVASCULAR EVENT.
Recruiting NCT05735405 - Aerobic Exercise and Cognitive Training in Patients With Stroke N/A
Recruiting NCT06107725 - Maimonides Minocycline in Stroke Study Phase 2/Phase 3